The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
Open Access
- 9 November 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (9) , 9666-9679
Abstract
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Keywords
This publication has 49 references indexed in Scilit:
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled TrialsJournal of Clinical Oncology, 2013
- The Evi5 family in cellular physiology and pathologyFEBS Letters, 2013
- Clonal competition with alternating dominance in multiple myelomaBlood, 2012
- Structure of a Glomulin-RBX1-CUL1 Complex: Inhibition of a RING E3 Ligase through Masking of Its E2-Binding SurfaceMolecular Cell, 2012
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaBlood, 2012
- The genetic architecture of multiple myelomaNature Reviews Cancer, 2012
- Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsHaematologica, 2011
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyThe Lancet, 2010
- The Transcriptional Corepressor CtBP: A Foe of Multiple Tumor SuppressorsCancer Research, 2009
- Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.Journal of Clinical Oncology, 1997